R. Bard, Inc. designs, manufactures, distributes, and sells medical, surgical, diagnostic, and patient care devices. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and invasive devices for treating peripheral vascular and end-stage renal diseases. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for treating prostate cancer; intermittent urinary drainage catheters and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey. C. R. Bard, Inc. operates as a subsidiary of Becton, Dickinson and Company.